| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a57036e4339d4d44cbb4ccce6c175cb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-196 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
2019-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbc0476fd189f6218dae40f443ec95d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22d07d4009301dc79abee4c5e5b7edfd |
| publicationDate |
2021-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112021007710-A2 |
| titleOfInvention |
pharmaceutical composition to treat aplastic anemia |
| abstract |
pharmaceutical composition to treat aplastic anemia. the present invention relates to a pharmaceutical composition for treating aplastic anemia, comprising romiplostim as an active ingredient. this pharmaceutical composition is characterized by: being administered subcutaneously once a week; and wherein for the first four weeks after the start of administration, the amount administered is 10 µg/kg/week in terms of romiplostim and from the fifth week, the amount is increased beyond 10 µg/kg/week, until 20 µg/kg/week in terms of romiplostim. |
| priorityDate |
2018-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |